Hidekuni Kaito Selected Research

KW-2450

1/2018

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hidekuni Kaito Research Topics

Disease

1	Breast Neoplasms (Breast Cancer) 01/2018
1	Exanthema (Rash) 01/2018
1	Hyperglycemia 01/2018
1	Hypersensitivity (Allergy) 01/2016
1	Neoplasms (Cancer) 01/2016

Drug/Important Bio-Agent (IBA)

1	KW-2450IBA 01/2018
1	afimoxifene (hydroxytamoxifen)IBA 01/2018
1	human ERBB2 proteinIBA 01/2018
1	Letrozole (Femara)FDA LinkGeneric 01/2018
1	Lapatinib (GW572016)FDA Link 01/2018
1	Aromatase (CYP19)IBA 01/2018
1	Drug CombinationsIBA 01/2018
1	Hormones (Hormone)IBA 01/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2016
1	Monoclonal AntibodiesIBA 01/2016
1	Heparin (Liquaemin)FDA LinkGeneric 01/2016
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2016
1	Epidermal Growth Factor (EGF)IBA 01/2016